Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT05620784
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • BPH
  • BPH With Urinary Obstruction
  • Hematuria
  • Same Day Discharge

Eligibility Criteria

Sex
MALE
Age
18 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

  • Furosemide — DRUG
    20mg of IV furosemide injection during the morcellation phase of HoLEP

Study Details

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .

Key Dates

Start date
Mar 1, 2023
Status verified
Sep 2023
Primary completion
Jun 6, 2023
Completion
Aug 1, 2024

Study Design

Enrollment
138 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Loop Diuretic (Furosemide)
    This group of patients will receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
  • No Intervention: Control
    This group of patients will not receive 20mg of IV furosemide during the morcellation phase of their HoLEP.

Primary Outcome Measure

Same-day discharge [ Time Frame: 90-days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611
Nicholas Dean, MD
[email protected]
Alyssa McDonald
[email protected]

Find similar trials in Chicago, IL

By research site
Northwestern University· Chicago, IL

Related Studies